Introduction
The canonical role of the osteocyte-derived circulating hormone fibroblast growth factor 23 (FGF23) is augmenting renal phosphate excretion by blocking tubular reabsorption and down-regulation of 1,25 dihydroxy-vitamin D synthesis. 1 However, the so-called critically ill patients, or in the general population. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] These data have suggested an independent association between high FGF23 levels and the risk for increased cardiovascular morbidity events (such as hospitalization for HF) and mortality in all the investigated patient groups. 18 Notably, the link between FGF23 and HF-associated endpoints was reported to be especially strong, while the association to atherosclerosis-related cardiovascular endpoints was modest. 19, 20 In HF patients the association between FGF23 levels and outcome was modified by variable Klotho levels and high FGF23 plus low Klotho levels showed specifically strong impact upon renin-angiotensin-aldosterone system inhibitor efficacy in terms of endpoint reduction. 21 Experimental in vivo data have supported these human cohort data by attributing a direct and causal role to FGF23 to left ventricular hypertrophy and dysfunction. 22, 23 The vast majority of previous studies investigating the association of serum FGF23 with outcome relied upon measuring C-terminal FGF23 (cFGF23). Enzyme-linked immunosorbent assays (ELISAs) measuring cFGF23 identify both the biologically active hormone (intact FGF23, iFGF23) as well as its degradation products. Early analysis performed in dialysis patients attributed a comparable value regarding risk assessment to both iFGF23 and cFGF23, 24 and a small cohort study in 100 HF patients recently confirmed this assumption. 14 However, the biological role of iFGF23 differs substantially from that of cFGF23 25 and, hence, relevant differences in the potency as biomarkers and risk predictors between the two forms are likely. Preliminary work in a cohort of patients undergoing coronary angiography for acute coronary syndrome suggested that the prognostic relevance of cFGF23 is superior for HF patients with reduced (HFrEF) compared to those with preserved ejection fraction (HFpEF), 26 but no previous study has so far taken into account the new European Society of Cardiology (ESC) ejection fraction strata of HF, which encompass three HF classes based on left ventricular ejection fraction (LVEF) into consideration. 27 Several unsolved issues remain about the reliability of FGF23 as a biomarker in HF given that recent studies question a direct, causal and independent role of FGF23 as causal cardiac risk factor. [28] [29] [30] [31] Data from the TIME-CHF (Trial of Intensified vs. Standard Medical Therapy in Elderly Patients With Congestive Heart Failure) cohort -a large prospective HF cohort with sophisticated long-term follow-up -can help to close these gaps. 32, 33 TIME-CHF offers the opportunity to target the following questions: Is there a relevant longitudinal change in FGF23 levels in HF patients? Does the reliability of FGF23 as a biomarker in HF differ between iFGF23 and cFGF23? Does the performance of FGF23 as a biomarker differ depending on strata of LVEF and HF subclass? Does FGF23 have a distinct role in prognosis assessment compared to established HF biomarkers such as B-type natriuretic peptide (BNP)?
Methods

The TIME-CHF cohort
Details about the TIME-CHF study were described previously. 32, 33 In brief, the study included patients aged 60 years or older with dyspnoea [New York Heart Association (NYHA) class ≥II, a history of hospitalization for HF within the last year, and an N-terminal proBNP (NT-proBNP) level of ≥400 ng/L in patients aged <75 years and a level of ≥800 ng/L in patients aged ≥75 years. Based on these criteria, 622 outpatients were included. Of these, 499 had an LVEF ≤45% by echocardiography, which was the cut-off for the definition of reduced LVEF in the original publication. 32 For the present analysis, patients were re-classified into three groups based on LVEF as suggested by the most recent ESC guideline definition 27 ; i.e. LVEF <40% = HFrEF, LVEF 40-49% = HF with mid-range ejection fraction (HFmrEF), LVEF ≥50% = HFpEF. TIME-CHF randomized patients to intensified NT-proBNP-guided vs. standard symptom-guided therapy for 18 months, with further follow-up for up to 5.5 years. Both treatment groups were stratified into two age groups of 60-74 years and ≥75 years. The study was approved by the Ethics Committees of each centre, and each patient gave written informed consent before entering the study. The primary result of the TIME-CHF trial was that HF therapy guided by NT-proBNP or symptom-guided therapy did not significantly improve the primary endpoint. 34 For each patient, every hospitalization, including cause of hospitalization and mortality, was recorded up to 5.5 years. 35 
Biochemistry
Blood samples were taken and stored at −80 ∘ C according to standard procedures.
From plasma samples collected at baseline, 3, 6 and 12 months, iFGF23 and cFGF23 were measured by TECO Medical using commercially available ELISAs (Immutopics, San Clemente, CA, USA). 36, 37 Intra-assay coefficient of variation (CV) for iFGF23 was 4.1% for 43 pg/mL and 2.0% for 426 pg/mL, while inter-assay CV were 9.1% for 46 pg/mL and 3.5% for 441 pg/mL. For cFGF23, CV was 2.4% for 33.7 RU/mL and 1.4% for 302 RU/mL, while inter-assay CV were 4.7% for 33.7 RU/mL and 2.4% for 293 pg/mL. Additional biomarkers were measured as previous described. 38 The present analysis is based on the currently available content of the biobank: not in all patients at all visits plasma was left and could be analysed. The number of included patients is reported for each analysis (refer to the Results section).
C-terminal FGF23 was measured in RU/mL, which was converted to pg/mL by multiplying by 1.5 and further converted to pmol/L by multiplying by 0.03831. Intact FGF23 was measured in pg/mL, which was converted to pmol/L by multiplying by 0.03831.
Statistical analysis
Data were analysed using SPSS version 25.0 (IBM SPSS Inc., Chicago, IL, USA). Normally distributed data are reported as mean and standard deviations (SD), non-normally distributed data as median and interquartile range (IQR). Both cFGF23 and iFGF23 values were not normally distributed and were therefore log-transformed for further analysis. Categorical data are presented as proportions (%).
Differences between groups were assessed using analysis of variance (ANOVA) for continuous data with a normal distribution, and Kruskal-Wallis test was used for continuous data with no normal distribution. Pearson 2 test was used for categorical data. A mixed model for repeated measures (RM) with a between subject factor was used to assess longitudinal biomarker variance and differences between the three groups. Mauchly's test of variance was used to assess if sphericity was violated, and if this was the case, the Greenhouse-Geisser correction was used. Analyses were corrected for multiple testing comparisons using the Bonferroni method.
First, a RM analysis from the original data was performed in the three groups, excluding patients with any missing data. Second, the RM analysis was performed after multiple imputation (n = 5) of missing biomarker concentrations at follow-up. Herein, missing biomarker levels of non-deceased subjects were replaced and depicted as separate lines to show the potential influence of missing data.
Survival was measured using the Kaplan-Meier method. Hazard ratios were calculated using Cox regression analyses for absolute biomarker concentrations. Spearman correlation was used to test associations between both cFGF23 and iFGF23 and other biomarkers. All P-values were two sided. A P-value of <0.05 was considered to be statistically significant. Data were analysed using SPSS version 25.0 (IBM SPSS Inc.). Power calculations for our Cox proportional hazard models were performed using XL-STAT; the method used is described in its package insert (https://www.xlstat.com/en/solutions/features/cox-model). The following input was used herein: SD of log-transformed cFGF23 which was 0.71; event rates and sample size as described above; alpha was set at 0.05. For multivariable models, the power calculation additionally uses the R 2 for a linear regression model of the included covariates regressed to log cFGF23 which was 0.17.
Results
Comparison between patients with heart failure with reduced, mid-range and preserved ejection fraction
Differences regarding baseline characteristics (anthropomorphic and clinical data) between these three groups based on LVEF are listed in Table 1 . Compared to HFrEF patients, patients with HFpEF were older, more likely to be female, were less likely to have an ischaemic cause of HF, and were less likely to be smokers. They had higher systolic blood pressure and a higher prevalence of atrial fibrillation. Characteristics of patients with HFmrEF were overall intermediate between HFrEF and HFpEF. Table 2 depicts serum levels of cardiac, renal, and inflammatory biomarkers at baseline stratified within the three strata of HF. Compared to HFrEF patients, patients with HFmrEF showed higher levels of cFGF23 and NT-proBNP, while renal function parameters and haemoglobin levels were lower ( Table 2) . Intact FGF23 levels at baseline were not significantly different between the three HF classes. Table 3 depicts how both iFGF23 and cFGF23 correlate with traditional HF biomarkers and with other biochemical indicators for relevant co-morbidities. Both iFGF23 and cFGF23 correlated positively with markers of cardiac damage and stress (NT-proBNP and high sensitivity troponin), inflammation (interleukin-6 and high-sensitivity C-reactive protein), as well as declining renal function (negative correlation with estimated glomerular filtration rate and positive correlation with cystatin C, uric acid, and urea).
Correlation analysis to other biomarkers related to heart failure
. Anaemia and iron metabolism parameters also showed significant correlations to both subtypes of FGF23 ( Table 3 ).
Influence of co-morbidities and severity of heart failure on fibroblast growth factor 23 levels
Patients with diabetes, chronic obstructive pulmonary disease and ischaemic HF did not differ in their levels of both iFGF23 and cFGF23 compared to non-diabetics, not having chronic obstructive pulmonary disease or patients with non-ischaemic HF aetiology, respectively ( Table 4 ). Gender (higher in females), age (higher >75 years), atrial fibrillation, history of renal failure or anaemia, atherosclerosis, and NYHA class (increasing levels with higher NYHA class) had significant impact upon cFGF23 levels but only some of these factors upon iFGF23.
Prognostic impact of fibroblast growth factor 23 on cardiovascular outcome
Of the 382 patients included in this analysis, 137 (36%) died during follow-up, 194 (51%) died or were hospitalized due to HF, and 300 (79%) died or were hospitalized due to any cause. In the patient group surviving 12 months (n = 324), 86 (27%) died, 138 (43%) either died or were hospitalized due to HF, and 250 (77%) were hospitalized due to any cause. The prognostic values of iFGF23 and cFGF23 regarding survival and HF-related hospitalization are depicted in Table 5 . In unadjusted analyses, log-transformed levels of cFGF23 concentration significantly predicted outcome. Log-transformed levels of iFGF23 also predicted outcomes at most, but not all time points in unadjusted analysis ( Table 5 ). After multivariable adjustment including NT-proBNP, the association between cFGF23 and outcome was less and for most analyses no longer of statistical significance ( Table 5 ). There was no significant difference regarding the predictive value of both iFGF23 and cFGF-23 between the three HF strata (HFrEF, HFmrEF, HFpEF) for any outcome (data not shown). Sample size for univariable analysis was sufficient at all time points and for all outcomes with a power of >90%. Sample size for multivariable analyses was limited (i.e. <80%) when the effect size fell below a hazard ratio of approximately 1.5 at baseline and 1.6 at month 12 for a 10-fold increase in FGF23 levels.
Longitudinal changes of fibroblast growth factor 23 over time
In 560 patients [HFrEF: 369 (66%); HFmrEF: 96 (17%); HFpEF: 95 (17%)], iFGF23 and cFGF23 were measured at least once at any of the four follow-up visits. As compared to those with both FGF23 forms measured at baseline (n = 382, online supplementary Table S1), the other 178 (32%) patients had less often a history of renal failure (49% vs. 60%, P = 0.02) or anaemia (20% vs. 31%, P = 0.006), were less symptomatic (NYHA class II, III, and IV, respectively: 32%, 57%, 11% vs. 20%, 65%, 15%; P = 0.007), less often ankle oedema (39% vs. 50%, P = 0.04) and haemoglobin was higher (136 ± 16 g/L Table S1 depicts the levels of iFGF23 and cFGF23 in HFrEF, HFmrEF and HFpEF at different time points during follow-up. Online supplementary Figures S1 and S2 show the log-transformed mean values of the available data as well five additional analyses with imputed data. Online supplementary Figure S1 shows that the observed patterns over time for cFGF23 in the three groups based on LVEF were not significantly influenced by missing data. In contrast, accuracy of imputation was less for iFGF23, particularly in patients with HFmrEF and HFpEF (online supplementary Figure S2) .
Both iFGF23 and cFGF23 showed a decrease at month 3 of the study in HFrEF patients and remained stable or slightly increased later in follow-up. A similar pattern was seen in were small. iFGF23 increased over time in both HFmrEF and HFpEF, but accuracy was less for these analyses due to missing data.
Discussion
Overall, the present TIME-CHF data do not support the previous appraisal about FGF23 being a strong and independent predictor of HF-related outcome and prognosis. In fact, the predictive power for both iFGF23 and cFGF23 was significantly reduced or disappeared with multifactorial adjustment including NT-proBNP. Moreover, our data show that risk assessment analyses using FGF23 in HF should carefully differentiate between iFGF23 and cFGF23, since reliability and performance as well as associations with co-morbidities were meaningfully different between the two forms. The present data amplify and modify our understanding about FGF23 as a biomarker in HF through several novel aspects: we directly compared FGF23 levels across all three subclasses of HF based on LVEF (as defined by the 2016 ESC guidelines 27 ). Of note, we detected significant differences in FGF23 blood levels between HFrEF, HFmrEF, and HFpEF patients. Most importantly, FGF23 did not increase linearly with declining LVEF suggesting that myocardial systolic dysfunction is not a major driving force for increasing FGF23 levels. Previous analyses have shown that other biomarkers also display different levels between HFpEF vs. HFrEF patients (e.g. C-reactive protein, high-sensitivity troponin, NT-proBNP 38 These data indicate that the different subclasses of HF exhibit varying amounts of activation of distinctive pathophysiological pathways. 38 This assumption is fuelled by remarkably different levels of co-morbidities and co-conditions between the three HF strata in TIME-CHF, i.e. differences in age, gender, glomerular filtration rate, and body mass index as well as distinct prevalence of ischaemic heart disease, smoking, and anaemia and the influence of at least some of these factors on FGF23 levels. Interestingly, our group of HFmrEF patients showed similar baseline levels of troponin, NT-proBNP, cystatin C and a lower glomerular filtration rate than HFrEF patients. Although this appears paradoxical, it most likely reflects the difficulty in classifying this new entity of HF patients, a phenomenon that has previously been reported and has sometimes been attributed to HF being a continuum and HFmrEF a transition phase to either HFpEF or HFrEF. Indeed, several relevant co-morbidities and concomitant conditions were associated with FGF23 level, e.g. signs of inflammation, declining renal function, and increasing levels of iron deficiency. Lower glomerular filtration rate, higher inflammatory markers and higher prevalence of anaemia were clearly related to higher FGF23 levels, specifically in the HFmrEF subgroup. 39 Similarly, there are some data suggesting that the association between FGF23 and incident HF is stronger for HFpEF than for HFrEF. 40 Since these associations were specifically strong for cFGF23 rather than for iFGF23 levels, we speculate that such co-existing conditions could primarily influence the rate of FGF23 degradation rather than its synthesis. This hypothesis is supported by recent findings that iFGF23 and cFGF23 levels react differently to intravenous iron replenishment in HF patients with iron deficiency. 41 How exactly co-existing conditions influence FGF23 metabolism needs to be determined and the biological relevance is still unclear.
Two other aspects support our skepticism about FGF23 as a stand-alone and causal HF biomarker: first, the predictive power Table 4 Intact and C-terminal fibroblast growth factor 23 levels at baseline in subgroups, irrespective of left ventricular ejection fraction iFGF23 (pmoL/L) cFGF23 (pmoL/L) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Values are given as median (interquartile range). cFGF23, C-terminal fibroblast growth factor 23; COPD, chronic obstructive pulmonary disease; HF, heart failure; iFGF23, intact fibroblast growth factor 23; NYHA, New York Heart Association. of cFGF23 was clearly superior to iFGF23, though the biological activity is stronger for the intact molecule. 25 Second, the prognostic impact of NT-proBNP outperforms both forms of FGF23 in terms of hospitalization and mortality prediction. After multivariable adjustment, the association between FGF23 and outcome largely disappeared. Although statistical power may have not been sufficient to find small prognostic impact in our multivariable models, the potential multivariable effect size of FGF23 is so small that we would need a very large cohort to reveal a statistical significant contribution to the model. With regard to clinical relevance, we can therefore conclude that the association between FGF23 and adverse outcome is limited at best in the light of the prognostic value of other markers included in our multivariable models, e.g. NT-proBNP. As such, the addition of FGF23 to the assessment of prognosis is neglectable.
Hence, the present data are in contrast to some of the previously published cohort studies which suggested a strong and independent association with all-cause mortality, cardiovascular mortality, or need for hospitalization 6, 12, 13, 15, 16 even after adjustment for (NT-pro) BNP. Our data are, however, in line with the CARE FOR HOMe study that initially showed a strong association between FGF23 and the development of HF in patients with chronic kidney disease, 19 but this association was lost when adjusting for NT-proBNP. 42 Previous studies investigating the role of FGF23 in HF patients were based only upon single-spot FGF23 measurements at baseline. Noteworthy, TIME-CHF also offers the exclusive opportunity to analyse serial FGF23 measurements in HF patients. In fact, the prognostic value of cFGF23 changed over time to some extent, which might explain some discrepant findings between studies. Two additional novel aspects arise: the longitudinal changes of iFGF23 and cFGF23 were not linear and numerically different between HFrEF, HFmrEF and HFpEF patients. Overall, we could detect no trend in the course of the two FGF23 forms and their blood levels were globally stable during follow-up without meaningful changes. Taking the minor importance of baseline FGF23 in this setting into account, the small absolute FGF23 changes over time most presumably do not induce clinical sequel.
Our data are in line with recent experimental findings also challenging FGF23's role in myocardial disease, e.g. primary elevations of FGF23 were found to be innocent and harmless to the rodent heart. 31 Such data call into question the direction of causality and underline speculations that actually heart disease per se contributes to elevated FGF23 levels (pointing towards reverse causality). 29, 30 Indeed, while early research suggested FGF23 to be a primarily renally controlled mediator with unfavourable cardiovascular action, 43 more recent data have called this previously held dogma into question. Indeed, it now seems that the already intricate relationship between the cardiovascular system and FGF23 is further complicated by the heart ability to release FGF23. 43 In this respect, we want to refer to the various significant correlations in TIME-CHF between both iFGF23 and cFGF23 and several other relevant cardiac, renal, and inflammatory biomarkers and co-morbidities established in clinical routine. 28 Our data point towards a different strength of association between cardiac risk factors and iFGF23 and cFGF23, respectively. One potential explanation for this discrepancy might emerge from important pre-analytical aspects: iFGF23, but not cFGF23, showed significant diurnal variation. C-terminal FGF23 had a significantly lower intra-individual variation than iFGF23 (8.3% vs. 18.3%) but higher inter-individual variation than iFGF23 (28.9% vs. 19.2%). Fourteen samples would be needed to estimate an individual's homeostatic set point (within 10%) for iFGF23 compared with only three samples for cFGF23. 37 The degradation of iFGF23 towards cFGF23 underlies external influences which might add to this variability. 41 There are limitations to our study. First of all, TIME-CHF was mostly an elderly collective of patients which, however, most likely represents the typical population of HF patients. Secondly, most patients were included shortly after an episode of acute cardiac decompensation but as the patients were followed up over time, the 3-month time point represents a stage of full compensation and assuming this as the baseline condition did not alter the results in a meaningful way. Thirdly, there was active medical management during the time course of the original study, potentially confounding some of the results. However, patients in both groups received intensifying treatment as recommended by the guidelines, representing a 'real-life' situation. Furthermore, owing to the real-life situation of the original study, in which blood was drawn at different time points during the day, we are unable to account for potential diurnal variations of FGF23 levels. Finally, although this is not the first study on the role of FGF23 in determining prognosis for HF patients, it adds to the understanding in the field, based on several novel features previously not or insufficiently addressed. Thus, we included a population that is representative for patients seen in clinical practice. In addition, we investigated both iFGF23 and cFGF23, which has not been done in a sufficiently large and/or defined cohort. Moreover, we investigated the whole range of LVEF. Finally, we studied repeated time points during follow-up, which is important to understand the role of a biomarker.
Conclusion
We investigated iFGF23 and cFGF23 as a biomarker and risk predictor in HF patients within the intensively characterized prospective HF cohort TIME-CHF. The present data regarding FGF23, its changes over time and its role in assessing the prognosis in HF are unique in several ways and modify our understanding about FGF23 as a biomarker by several novel and important aspects. Analysing cFGF23 or iFGF23 adds limited information to risk prediction and outcome analysis in HF patients. Additionally, our data challenge the hypothesis about a causal link of FGF23 elevations with myocardial disease. Hence, the TIME-CHF data do not support FGF23 (neither iFGF23 nor cFGF23) as a clinically relevant biomarker in HF patients.
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